SUPN Stock — Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. (SUPN)

Updated October 16, 2026.

SUPN is a Stock. Total return is 605.4% over the past 14.5 years, 8.7 points ahead of SPY at 596.7%.

Supernus Pharmaceuticals is a biopharmaceutical company developing and commercializing treatments for central nervous system diseases, including FDA-approved products for ADHD, Parkinson's disease, epilepsy, and other neurological conditions, along with several candidates in clinical trials. The company does not currently have an established distribution program. This stock may appeal to investors seeking exposure to the pharmaceutical and healthcare sectors, though it is a development-stage company without regular income distributions.

SUPN performance versus SPY

Price and return data through 2026-10-16.

Total return is 605.4% over the past 14.5 years, 8.7 points ahead of SPY at 596.7%. Over the past year its total return — price change plus distributions reinvested — is -23.9%. Its deepest 1-year drawdown was 33.5%.

SUPN key facts

Asset type

Stock

Asset class

Equity

Inception date

05/01/2012

Distribution frequency

None

Last close

$37.88 (as of 2026-10-16)

Market cap

$2,205,530,537

Average volume

1441614.0

Beta

0.554

Payout ratio

0.0%

Forward P/E

20.1613

EPS

$-1.92

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SUPN risks and drawbacks

The deepest 1-year drawdown on record here is 33.5%.

Who may consider SUPN — and who may not

It is a weaker fit for investors who need monthly cash flow (SUPN does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on SUPN

• All tickers starting with S

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions